BioSpace News Archive

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study.

Seagen Inc. (Nasdaq:SGEN) today announced that new data for ADCETRIS® (brentuximab vedotin), including five oral presentations, will be featured at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.

MorphoSys AG announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology Annual Meeting from December 11-14 in Atlanta, Georgia United States.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting.

Biosight Ltd., today announced that an abstract has been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting.

Lantern Pharma (NASDAQ: LTRN), today announced that Lantern Pharma’s abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the Treatment of Hypertension.

Co-Diagnostics, Inc. (Nasdaq: CODX), announced today that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated according to the United Kingdom Health Security Agency’s (“UKHSA”) Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”) and is available for sale in the UK under the Regulation.

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.